

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/534,082
Filing Date	May 5, 2005
First Named Inventor	S. Hinuma
Art Unit	tba 1645
Examiner Name	tba Swartz
Attorney Docket Number	3118 USOP

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Page
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
/RS/		WO 00/31261	06-02-2000	Cadus Pharmaceutical Corp.		
/RS/		WO 01/57074	08-09-2001	Gov't of United States of Am.		

Examiner Signature	/Rodney Swartz/	Date Considered	06/19/2007
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/534,082
Filing Date	May 5, 2005
First Named Inventor	S. Hinuma
Art Unit	tba 1645
Examiner Name	tba Swartz
Attorney Docket Number	3118 US0P

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RS/		KLEIN, C. et al, "Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast," <u>Nature Biotechnology</u> , (Dec 1998), Vol 16, No. 13, pages 1334-1337	
/RS/		LI, B-Q. et al., "The synthetic peptide WKYMVm attenuates the function of the chemokine receptor CCR5 and CXCR4 through activation of formyl peptide receptor-like 1," <u>Blood</u> , (May 2001), Vol. 97, No. 10, pages 2941-2947	

Examiner Signature	/Rodney Swartz/	Date Considered	06/19/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	Based on PC 72P 2003014936
Filing Date	Intl. Filing 06 NOVEMBER 2003
First Named Inventor:	Shuji HINUMA
Art Unit	tba 1645
Examiner Name	tba Swartz
Attorney Docket Number	3118 USOP

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^d
		Country Code ³ *Number ⁴ *Kind Code ⁶ (if known)	MM-DD-YYYY			
/RS/	A1	WO 03/106683 A1 - Abstract only	12/24/2003	Takeda Chemical Industries		
/RS/	A2	WO 2004/008141 A1 - Abstract only	01/22/2004	Takeda Chemical Industries		

Examiner Signature	/Rodney Swartz/	Date Considered	06/19/2007
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JC06 Rec'd PCT/PTO 05 MAY 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Application Number

Based on PCT/JP2003/014138

Filing Date

Intl. Filing 06 NOVEMBER 2003

First Named Inventor

Shuji HINUMA

Art Unit

tba 1645

Examiner Name

tba Swartz

Attorney Docket Number

3118 USOP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RS/	A3	P.M. MURPHY, et al., "A Structural Homologue of the N-Formyl Peptide Receptor", The Journal of Biological Chemistry, (1992), pp. 7637-7643, Vol. 267, No. 11.	
	A4	Y. LE, et al., "Receptors for Chemotactic Formyl Peptides as Pharmacological Targets", International Immunopharmacology, (2002), pp. 1-13, Vol. 2.	
	A5	Y. LE, et al., "Amyloid Beta42 Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1", The Journal of Neuroscience, (2001), RC123, 1 of 5, Vol. 21.	
	A6	H. YAZAWA, et al., "Beta Amyloid Peptide (AlphaBeta42) is Internalized via the G-Protein-Coupled Receptor FLPL1 and Forms Fibrillar Aggregates in Macrophages", The FASEB Journal, (2001), pp. 2454-2462, Vol. 15.	
	A7	T. CHRISTOPHE, et al., "The Synthethetic Peptide Trp-Lys-Tyr-Met-NH2 Specifically Activates Neutrophils...", The Journal of Biological Chemistry, (2001), pp. 21585-21593, Vol. 276, No. 24.	
	A8	A. BETTEN, et al., "A Proinflammatory Peptide fro Helicobacter Pylori Activates Monocytes to Induce Lymphocyte Dysfunction and Apoptosis", The Journal of Clinical Investigation, (2001), pp. 1221-1228, Vol. 108, No. 8.	
	A9	DE YANG, et al., "Human Dendritic Cells Express Functional Formyl Peptide Receptor-Like-2 (FPRL2) Throughout Maturation", Journal of Leukocyte Biology, (2002), pp. 598-607, Vol. 72.	
	A10	M. PERRETTI, et al., "Endogenous Lipid-and Peptide-Derviced Anti-Inflammatory Pathways Generated with Glucocorticoid and Aspirin Treatment Activate the Lipoxin A4 Receptor", Nature Medicine, (2002), pp. 1296-1302, Vol. 8, No. 11.	
	A11	Y. CUI, et al., "Potential Role of the Formyl Peptide Receptor-Like 1 (FPRL 1) in Inflammatory Aspects of Alzheimer's Disease", Journal of Leukocyte Biology, (2002), pp. 628-635, Vol. 72.	
↓	A12	S.M. SHAWAR, et al., "Peptides From the Amino-Terminus of Mouse Mitochondrially Encoded NADH Dehydrogenase Subunit 1 are Potent Chemoattractants", Biochemical and Biophysical Research Communications, (1995), pp. 812-818, Vol. 211, No. 3.	

Examiner
Signature

/Rodney Swartz/

Date

Considered

06/19/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JC06 Rec'd PCT/PTO 05 MAY 2008

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	Based on PCT/JP2003/014138
		Filing Date	Intl. Filing 06 NOVEMBER 2003 10/534082
		First Named Inventor	Shuji HINUMA
		Art Unit	tba 1645
		Examiner Name	tba Swartz
Sheet 3	of 3	Attorney Docket Number	3118 USOP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RS/	A13	H. CARP, "Mitochondrial N-Formylmethionyl Proteins as Chemoattractants for Neutrophils", J. Exp. Med., (1982), pp. 264-275, Vol. 155.	
/RS/	A14	S. ANDERSON, et al., "Sequence and Organization of the Human Mitochondrial Genome", Nature, (1981), pp. 457-465, Vol. 290.	
/RS/	A15	Y. LE, et al., "Formyl-Peptide Receptors Revisited", Trends in Immunology, (2002), pp. 541-548, Vol. 23, No. 11.	

Examiner Signature	/Rodney Swartz/	Date Considered	06/19/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.